http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/ News About Tech, Money and Innovation Mon, 23 Nov 2009 07:11:08 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/comment-page-1/#comment-800551 Life-science briefing: Thursday, March 27, 2008 » VentureBeat Fri, 28 Mar 2008 15:20:02 +0000 http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/#comment-800551 [...] joins a number of other companies pursuing similar strategies, including Adnexus Therapeutics, which sold itself to Bristol-Myers Squibb for $430 million, and Molecular Partners, a Swiss [...] [...] joins a number of other companies pursuing similar strategies, including Adnexus Therapeutics, which sold itself to Bristol-Myers Squibb for $430 million, and Molecular Partners, a Swiss [...]

]]> http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/comment-page-1/#comment-742184 VentureBeat » Life sciences briefing: Friday, Jan. 18, 2007 Sat, 19 Jan 2008 01:53:23 +0000 http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/#comment-742184 [...] can see our previous coverage of Elixir here and here. For more stories on VentureBeat Life Sciences, click here.Tagged Alzheimers disease, [...] [...] can see our previous coverage of Elixir here and here. For more stories on VentureBeat Life Sciences, click here.Tagged Alzheimers disease, [...]

]]> http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/comment-page-1/#comment-606902 VentureBeat » Life sciences briefing: Wednesday, Oct. 31, 2007 Wed, 31 Oct 2007 16:57:57 +0000 http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/#comment-606902 [...] JapanBridge, an MPM Capital-founded company we wrote about here, SymBio essentially aims to acquire drugs or drug candidates from elsewhere in order to win [...] [...] JapanBridge, an MPM Capital-founded company we wrote about here, SymBio essentially aims to acquire drugs or drug candidates from elsewhere in order to win [...]

]]> http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/comment-page-1/#comment-588632 VentureBeat » Life sciences briefing: Friday, Oct. 19, 2007 Sat, 20 Oct 2007 12:40:23 +0000 http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/#comment-588632 [...] This particular field happens to be booming — we’ve previously covered competitors JenaValve, AorTx and [...] [...] This particular field happens to be booming — we’ve previously covered competitors JenaValve, AorTx and [...]

]]> http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/comment-page-1/#comment-574198 VentureBeat » Compendia Bioscience, cancer-genomics data miner, leverages the Web for biodata analysis Thu, 11 Oct 2007 17:26:42 +0000 http://venturebeat.com/2007/09/24/life-sciences-briefing-monday-sept-24-2007/#comment-574198 [...] programs launched by companies such as NextBio and GenomeQuest. (See our previous coverage here and here, respectively.) The main difference here is that Compendia is focused more on gene-expression data [...] [...] programs launched by companies such as NextBio and GenomeQuest. (See our previous coverage here and here, respectively.) The main difference here is that Compendia is focused more on gene-expression data [...]

]]>